ICH pharmaceutical stability testing is an important component of all protein/peptide biopharmaceutical development, especially in support of IND/NDA submission activities. CD Formulation offers a wide range of ICH stability testing services for large molecule protein/peptide drugs, supporting the development of efficient standard or customized storage conditions to meet your real-time, accelerated, or forced degradation stability study requirements.
ICH stability testing is designed to monitor and evaluate changes in protein/peptide APIs and finished pharmaceutical products (FPP) over a period of time under the influence of different factors such as environmental conditions (temperature, humidity, light), packaging materials, and container closure systems. Data from these studies not only determine recommended storage conditions, shipping conditions, and shelf life but also help predict their in vivo stability and efficacy.
According to international guidelines (ICH, FDA, and WHO), stability studies must be performed on drug substances (DS) and drug products (DP) to ensure the quality and efficacy of drugs throughout their life cycle in a more efficient and time-saving manner.
Fig.1 Objectives of stability testing. (González-González O, et al., 2022)
To advance your protein/peptide drug from discovery to regulatory approval to commercial manufacturing, you must understand how your product performs under both routine and stress conditions. Following the ICH Stability Testing Guidelines, CD Formulation provides stability indicating method development and validation for protein/peptide active ingredients and final products.
Our stability testing team uses pharmacopoeial or in-house developed and validated methods to provide compliant stability testing data, including identification and quantification of possible degradation products and impurities, and routine testing of finished products such as assay, moisture, hardness, solubility, disintegration, etc.
We have a broad range of stability testing conditions covering ICH climatic zones, while also offering custom storage capabilities:
CD Formulation implements and executes pharmaceutical stability testing programs for protein and peptide biologics, with a particular focus on specialty formulations - inhaled, including nasal and pulmonary, and injectable. We provide stability testing services to help you understand how your product performs under a variety of conditions - all in compliance with ICH guidelines and compliance requirements of leading global regulatory agencies, in preparation for commercial launch.
Our scientists have strong expertise in stability testing of inhaled products, available testing includes:
Our injection stability research includes influencing factor testing, accelerated testing, and long-term testing. If necessary, intermediate condition tests should be conducted. Low-temperature tests and freeze-thaw tests are recommended for injections that may be unstable at low temperatures. Available testing items include:
Published Data
Technology: Liquid-chromatograph-andem mass spectrometry and size-exclusion chromatography-multi-angle light scattering (HPLC-SEC-MALS)
Journal: Anal Bioanal Chem.
IF: 3.431
Published: 2023
Results:
The authors describe a model based on the accelerated stability assessment procedure (ASAP) to evaluate the biosimilarity of original, innovator, and generic drugs in terms of stability. The innovator infliximab and two different types of biosimilars were used as model drugs. Several PTM hotspots including methionine oxidation and asparagine deamidation were characterized using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The formation of aggregates and free-chain fragments was characterized using size exclusion chromatography-multi-angle light scattering (SEC-MALS-UV/RI). The results showed a correlation between the ASAP model and the long-term stability data of samples stored in intravenous bags, indicating the stability of the mAb.
Fig. 2 Proportions of (A) oxidation for methionine and tryptophane hotspots after incubation in 0.05% H2O2 for Remicade®, Remsima® and Flixabi®. (Legrand P, et al., 2023)
With over 20 years of experience in stability studies and a comprehensive understanding of the latest developments in regional, national, and ICH stability study guidelines, CD Formulation provides truly flexible, high-quality stability testing services for protein/peptide biopharmaceutical projects for clients around the world. Please feel free to contact us if you are interested in our services or have further questions. We look forward to working with you.
References